TORONTO, Sept. 20, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that preclinical proof-of-concept data comparing its…

Source

Previous articlePT263 – Michelle Janikian – 920: The Magic Mushroom Holiday
Next articlePsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1